|Summary sheet: ETH-LAD|
|Substitutive name||6-Ethyl-6-nor-lysergic acid diethylamide|
|Routes of Administration|
6-Ethyl-6-nor-lysergic acid diethylamide (also known as N-Ethyl-nor-lysergic acid N,N-diethylamide, N-Ethyl-nor-LSD, and ETH-LAD) is a lesser-known novel psychedelic of the lysergamide class that produces LSD-like psychedelic effects when administered. It is structurally related to psychedelic lysergamides like LSD, AL-LAD, and PRO-LAD.
This compound has been shown to be moderately to significantly more potent than LSD itself in animal studies with an active dose reported at between 40 and 100 micrograms. Anecdotal reports suggest that while it produces similar effects to LSD at low to common doses, it displays a notably divergent effects profile at higher doses, sometimes described as producing "algorithmic" and "warped" visual and auditory distortions, combined with a more "introspective" and "analytical", if not more "neutral" head space.
ETH-LAD has also been reported to more readily produce adverse physical effects such as severe and persisting nausea, temperature dysregulation, and generalized bodily discomfort, particularly at higher doses. This has been speculated to owe itself to an unusually sensitive and unpredictable dose-response curve, as low to common dose experiences are generally described as being very manageable and non-threatening.
Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-LAD, and it has little history of human usage. It has been marketed alongside psychedelic lysergamides like 1P-LSD and AL-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors. Along with its sensitive dose-response and potentially concerning physical side effects, many reports suggest that this substance may be overly difficult to use safely for those who are not experienced with hallucinogens. It is highly advised to use harm reduction practices if using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 Literature
- 9 References
ETH-LAD, or 6-ethyl-6-nor-lysergic acid diethylamide, is a synthetic alkaloid of the lysergamide chemical class. ETH-LAD is a structural analog of lysergic acid with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative and has both overlapping tryptamine and phenethylamine skeletons embedded within its molecular structure (although it is principally classified as a tryptamine). ETH-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid).
ETH-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton as is the case with LSD; this is represented by the nor- prefix. Instead, ETH-LAD is substituted at R6 with an ethyl group. At carbon 8 of the quinoline, a N,N-diethyl carboxamide is bound in the same configuration of LSD.
ETH-LAD is a chiral compound with two stereocenters at R5 and R8. ETH-LAD, also called (+)-D-ETH-LAD, has an absolute configuration of (5R, 8R).
As with LSD and other compounds in the lysergamide family, ETH-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from ETH-LAD's efficacy at the 5-HT2A receptors, although it is likely that like LSD, ETH-LAD also binds to a wide range of different receptors, including multiple different subtypes of serotonin receptors as well as dopamine and adrenoreceptors well.
However, the role of these interactions and how they result in the psychedelic experience remains subject to on-going scientific investigation.
While the subjective effects of ETH-LAD are reported to largely overlap with those of LSD, it has been noted for the tendency to be more visually and auditorily distortive, introspective, analytical and immersive yet with the capacity to produce pronounced discomforting physical effects like severe and persisting nausea, and temperature dysregulation past the common dose range in a seemingly unpredictable manner.
Due to its high potency and sensitive dose-response, many reports also indicate that the effects of this substance may be overly intense for those who are not already very experienced with psychedelics. Users are advised to approach this substance with caution, use a full array of harm reduction practices, and pay close attention to their physical conditions and environment if using this substance.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation & Sedation - In terms of its effects on the physical energy levels of the user, ETH-LAD is regarded as being able to produce a spectrum of either predominantly stimulating or sedating effects, often alternating throughout the experience, sometimes to the point of feeling forced. This is in distinction to other, more commonly used psychedelics such as psilocybin which are more consistent in producing sedation and relaxation.
- Spontaneous physical sensations - The "body high" of ETH-LAD can be characterized as prominent in comparison to its accompanying visual and cognitive effects. Like LSD, it can behave as a fast-moving, sharp and location specific or generalized tingling sensation, although this feeling is not necessarily pleasant and often manifests in a neutral way. For some, it is manifested spontaneously at different, unpredictable points throughout the experience, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached, which users tend to report as feeling "neutral", with the emphasis instead placed on alterations in the "head space".
- Physical euphoria - This component can occur with the development of spontaneous physical sensations, but is not as consistent as it is with LSD, and has more of a tendency to spontaneously produce mild to strong neutral if not uncomfortable physical sensations such as those that can be experienced on 2C-E.
- Bodily pressures - This can manifest as either negative or pleasant bodily sensations capable of occurring anywhere, but particularly in the central areas of the body including the inner cavities like the chest or the lungs.
- Temperature regulation suppression - This component can occur with the use of any lysergamide or psychedelic, but reports suggest it may be pronounced in ETH-LAD. It is highly advised that users of this compound, especially at heavier doses, monitor their bodily temperature and use techniques like hot showers or cold packs to regulate their core and brain temperature throughout the experience, and to generally always maintain proximity to a climate-controlled environment.
- Nausea - In comparison to traditional psychedelics, ETH-LAD has been noted for being able to produce nausea and other "body load" type feelings more readily, potentially at any point during the experience but most prominently during the "come up".
- Appetite suppression
- Headaches - This effect typically occurs either spontaneously, or on the comedown of higher doses than is thought the body can handle.
- Bodily control enhancement
- Stamina enhancement - This is generally mild in comparison to traditional stimulants.
- Dehydration - Users are advised to pay careful attention to both their water and electrolyte levels when taking ETH-LAD, being cautious to neither under nor over drink.
- Difficulty urinating or Frequent urination - While lysergamides are known for their interactions with the kidneys and bladder, ETH-LAD seems to affect it more so than LSD.
- Increased blood pressure
- Increased heart rate
- Increased perspiration
- Muscle contractions
- Muscle cramps - This component can occur with the use of any lysergamide or psychedelic, but reports suggest it can be especially pronounced with this substance.
- Muscle spasms - This component can occur with the use of any lysergamide or psychedelic, but reports suggest it can be especially pronounced with this substance.
- Gustatory hallucinations
- Olfactory hallucinations
- Mouth numbing
- Excessive yawning
- Watery eyes
- Pupil dilation
- Vasoconstriction
- Teeth grinding - This component is considerably less intense when compared with that of substances like MDMA and happens more readily than with related substances like LSD, perhaps owing to the greater degree of stimulation it produces.
- Seizure - This is an effect whose likelihood is largely extrapolated from the seizures that have been reported from the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as states of dehydration, fatigue or undernourishment. Although the extent to which this differs from the seizure risk posed by LSD is totally unknown, it is highly advised that users should always be prepared for the worst case scenario.
ETH-LAD has been noted by the community as displaying a remarkable and unique range of visual effects that are often described as "synthetic", "digital", and highly complex in feeling. It has been noted for its capacity to produce profoundly complex visual hallucinations, including higher level geometry, in a much more reliable and consistent manner than other members of the lysergamide family.
All of the components listed below are generally considered more pronounced than they are for LSD at equipotent dosages.
All of the components listed below are generally considered to be more pronounced than they are for LSD at equipotent dosages.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- After images
- Scenery slicing
- Symmetrical texture repetition
- Environmental geometry
The visual geometry that is commonly present throughout this experience can be generally described as more similar in appearance to that of DPT or 2C-E than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, structured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, immersive in-depth and consistent in intensity. At higher dosages, it may almost consistently result in states of Level 8A or Level 8B visual geometry.
ETH-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects include:
- Machinescapes - This component is moderately more likely to occur than with LSD, particularly with strong to heavy doses. These machinescapes should not be confused for the ones commonly experienced on salvia however.
- Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)
The cognitive effects of ETH-LAD can be broken down into several components which progressively intensify proportional to dosage. In comparison to other psychedelics such as psilocybin mushrooms and ayahuasca, ETH-LAD is often described as significantly more stimulating and fast-paced in terms of the specific style of thought stream(s) produced and contains a large number of potential effects. It should be noted that that higher doses appear to be readily capable of producing cognitive impairment and general sensory processing overload for reasons that are not currently understood.
The most prominent of these cognitive effects generally include:
- Analysis enhancement - This component seems to be one of the uniquely pronounced features of this substance relative to other chemicals in its class. The kind of analysis enhancement experienced has drawn comparisons to the headspaces of drugs like 2C-E and DOM, with a more emotionally neutral charge than LSD or AL-LAD.
- Conceptual thinking
- Thought acceleration - While this component can occur with the use of any lysergamide psychedelic, reports suggest it can be especially pronounced with this compound until the heavy dose range is reached.
- Thought connectivity
- Thought organization
- Cognitive euphoria
- Personal bias suppression
- Immersion enhancement
- Novelty enhancement - This component can occur with the use of any lysergamide psychedelic, but reports suggest it can be especially pronounced with this compound.
- Anxiety & Paranoia - These effects do not occur as commonly at low to moderate doses, particularly when the basic rules of set and setting are taken into account, but can be overwhelming at higher doses. The negative sensations produced by this effect are seemingly more likely to manifest when the substance is combined with cannabis. Therefore, this combination should be used with extreme caution if one is not experienced with psychedelics, meaning that the user should adequately pace themselves while taking only a fraction of their usual amount.
- Language suppression - This effect can be described as a perceived inability or general unwillingness to talk aloud despite feeling perfectly capable of formulating coherent thoughts within one's internal narrative. It appears to be less prominent at low doses and more prominent at high doses compared to related lysergamides like LSD.
- Memory suppression - This component and subcomponent may happen more readily and unpredictably than with other psychedelic compounds. For this reason, harm-reduction practices like having a trip sitter arranged beforehand when taking higher doses of this substance are highly advised.
- Confusion - Some users have reported that the strong hallucinatory and memory suppressing effects of ETH-LAD at higher doses may lend itself more readily to states of confusion and disorientation than other psychedelics.
- Increased music appreciation
- Déjà vu
- Thought loops - This component can occur with the use of any lysergamide or psychedelic, but reports suggest it can be especially pronounced with ETH-LAD when it does occur.
- Time distortion - This component has been reported to be particularly pronounced relative to other psychedelics.
- Multiple thought streams - This component can occur with the use of any lysergamide psychedelic, but reports suggest it can be especially likely to occur with this compound.
All of these components are generally considered to be inexplicably more pronounced than they are for LSD at equipotent dosages. ETH-LAD has been noted for the sheer depth and range of auditory hallucinations and alterations it is capable of producing, for reasons that are yet poorly understood.
- Auditory enhancement
- Auditory hallucinations - The audio hallucinations produced by this compound seem to be more prominent compared to many other psychedelics. The reasons are not yet understood, but those who choose to use this substance are advised to be prepared for the uncontrollable auditory hallucinations this compound can produce, if one is predisposed to them.
- Auditory distortion - This component is uniquely pronounced relative to other memebers of the lysergamide family. At doses above the common dose, they are liable to either be neutral if not mildly disturbing or intriguing.
Anecdotal reports which describe the effects of this compound within our experience index include:
- Experience:300µg ETH-LAD - Turned Inside Out
- Experience:A combination of DOC, 5-MAPB, 5-MeO-DMT, ETH-LAD, Cannabis, Pentedrone
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational ETH-LAD use in humans does not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because ETH-LAD is a research chemical with very little history of human usage.
Anecdotal reports from those who have tried ETH-LAD suggests that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (although nothing can be guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
ETH-LAD is not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is generally considered to have a built-in, self-regulating aspect to it, although cases of its abuse have been reported.
Tolerance to the effects of ETH-LAD build almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to return to baseline (in the absence of further consumption). ETH-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of ETH-LAD all psychedelics will display a reduced effect.
Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. Note that the substances listed below refer to LSD specifically; however, there is no reason to believe they do not apply equally, if not even more so, to relatively unstudied and structurally similar compounds like ETH-LAD as well.
- Tramadol - Tramadol lowers seizure threshold and psychedelics may cause occasional seizures.
- Stimulants - Stimulants may provoke anxiety or thought loops.
- Lithium - Due to its similiarity to LSD, individuals who take lithium for bipolar disorder or other psychiatric conditions should not take ETH-LAD. There are numerous anecdotal reports of seizures and or psychosis from the LSD-lithium combination.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
It is unclear in many countries whether this compound is legal or not and one should take precaution by assuming it is illegal to avoid potential legal issues.
- Austria: ETH-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
- Latvia: ETH-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1st, 2015.
- Switzerland: ETH-LAD is scheduled as of the 1st of December 2015.
- United Kingdom: As of January 7th, 2015, ETH-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
- United States - ETH-LAD is unscheduled in the United States. It may be considered an analogue of LSD (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or scientific research could be prosecuted as crimes under the Federal Analogue Act.
- Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
- Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
- Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
- Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.
- National Center for Biotechnology Information. PubChem Compound Database; CID=44457783, https://pubchem.ncbi.nlm.nih.gov/compound/44457783 (accessed May 5, 2017).
- Shulgin, A., & Shulgin, A. (1991). Erowid Online Books: "TIHKAL" - #12. ETH-LAD. Retrieved April 14, 2017.
- Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/0.1021/jm00147a022
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- Tripsit Factsheets - LSD | http://drugs.tripsit.me/lsd
- Fisher, D. D., & Ungerleider, J. T. (1967). Grand mal seizures following ingestion of LSD. California Medicine, 106(3), 210. PMCID: PMC1502729
- Question ID: 2837 (Ask Erowid) | https://www.erowid.org/ask/ask.php?ID=2837
- Tripsit Factsheets - LSD | http://drugs.tripsit.me/lsd
- https://erowid.org/chemicals/lsd/lsd_interactions.shtml | LSD Interactions by Erowid
- Wanderli. "A Nice Little Trip to the Hospital: An Experience with Lithium & LSD (ID 83935)". Erowid.org. Oct 3, 2010.
- MissDja1a. "Having a Seizure and Passing Out: An Experience with Lithium & LSD (ID 75153)". Erowid.org. Dec 16, 2008.
- Reddit account of seizure on LSD + Lithium | https://www.reddit.com/r/Psychonaut/comments/17uspp/please_read_a_cautionary_tale_concerning_lsd/
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) | http://likumi.lv/doc.php?id=121086
- Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeich nisverordnung, BetmVV - EDI) | https://www.admin.ch/opc/de/official-compilation/2015/5093.pdf
- ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.